2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American …
SR Ommen, S Mital, MA Burke, SM Day… - Journal of the American …, 2020 - jacc.org
The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …
initial extensive evidence review, which included literature derived from research involving …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of …
SR Ommen, S Mital, MA Burke, SM Day… - Journal of the American …, 2020 - jacc.org
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …
provides recommendations and algorithms for clinicians to diagnose and manage …
JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias
A Nogami, T Kurita, H Abe, K Ando, T Ishikawa… - Circulation …, 2021 - jstage.jst.go.jp
Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College …
SM Al-Khatib, WG Stevenson, MJ Ackerman… - Journal of the American …, 2018 - jacc.org
The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …
evidence-based. An initial extensive evidence review, which included literature derived from …
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of …
Authors/Task Force Members, SG Priori… - Ep …, 2015 - academic.oup.com
The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …
The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the …
P Lancellotti, PA Pellikka, W Budts… - European Heart …, 2016 - academic.oup.com
A unique and highly versatile technique, stress echocardiography (SE) is increasingly
recognized for its utility in the evaluation of non-ischaemic heart disease. SE allows for …
recognized for its utility in the evaluation of non-ischaemic heart disease. SE allows for …
An expert consensus document on the management of cardiovascular manifestations of Fabry disease
A Linhart, DP Germain, I Olivotto… - European journal of …, 2020 - Wiley Online Library
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic
variants in the α‐galactosidase A (GLA) gene that leads to reduced or undetectable α …
variants in the α‐galactosidase A (GLA) gene that leads to reduced or undetectable α …
[PDF][PDF] 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
PM Elliott, A Anastasakis, MA Borger… - Polish Heart …, 2014 - journals.viamedica.pl
Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)
C O'Mahony, F Jichi, M Pavlou, L Monserrat… - European heart …, 2014 - academic.oup.com
Aims Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death
(SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail …
(SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail …